Global Psoriasis Drugs Market 2021, Scope and Pipeline Analysis of Top Manufacturers Profiles, Market Growth Factors during forecast year 2020-2030

September 09 21:18 2021
Global Psoriasis Drugs Market 2021, Scope and Pipeline Analysis of Top Manufacturers Profiles, Market Growth Factors during forecast year 2020-2030
“Global Psoriasis Drugs Market and Pipeline Analysis till 2030”
Global Psoriasis Drugs Market, By Therapeutic Class (Tumor Necrosis Factor-inhibitors, Interleukin-inhibitors, Vitamin D analogues), By Treatment (Topicals, Systemic, and Biologics), By Type (Plaque Psoriasis, Psoriatic Arthritis and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies) and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) – Trends, Analysis and Forecast till 2030

Global Psoriasis Drugs Market accounted for US$ 15.85 billion in 2020 and is estimated to be US$ 37.07 billion by 2030 and is anticipated to register a CAGR of 8.90%. Psoriasis is a difficult, ongoing, deforming, non-transferable, and crippling immune system sickness with a restricted therapy choice. Because of which, it contrarily affects the patient’s life. Psoriasis includes the nails, skin, and furthermore connected with a few comorbidities. Also, it causes incredible social, enthusiastic and actual weight and frequently prompts weakness. Inability, disfiguration, and clear loss of Therapeutic Classivity are normal difficulties for individuals experiencing psoriasis. Besides, psoriasis is of five sorts, specifically Guttate, Plaque, Pustular, Inverse, and Erythrodermic. The disturbing expansion in the quantity of psoriasis patient eventually raises the interest for appropriate treatment management.

 

Prophecy Market insights report “Psoriasis Drugs and Pipeline Analysis” provides comprehensive insights about 40+ companies and 100+  pipeline analysis. It comprises Psoriasis pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Psoriasis therapeutics assessment by therapeutic class, treatment, region and further highlights the inactive Psoriasis pipeline products. 

 

Pipeline Analysis:

 

Study Title

Phase

Conditions

Evaluation of DD-25 Topical Cream for the Treatment of Psoriasis Vulgaris 

 

Phase 1, 2

Psoriasis Vulgaris

Safety and Efficacy of UC-MSCs in Patients With Psoriasis Vulgaris

Phase 1, 2

Psoriasis Vulgaris

Therapeutic Drug Monitoring of Ixekizumab in Psoriasis Patients

Phase 4

Psoriasis Vulgaris

Adjusted Brodalumab Dose Compared With Standard Brodalumab Dose in Subjects With Moderate-to-severe Plaque Psoriasis and ≥120 kg Body Weight

Phase 4

Psoriasis Vulgaris

Therapeutic Drug Monitoring of Guselkumab in Psoriasis Patients

Phase 4

Psoriasis Vulgaris

Therapeutic Drug Monitoring of Secukinumab in Psoriasis Patients.

Phase 4

Psoriasis Vulgaris

 

Analyst View:

Rising awareness regarding disease, increasing number of reimbursement strategies for biologics, and advanced technological and diagnostic tools are likely to drive the global psoriasis drugs market. Increasing Food and Drug Administration (FDA) approval for the new drugs and therapies for the psoriasis disease is expected to surge the growth of the global market to a significant extent. Besides, to tap into an emerging market, the manufacturer is constantly improving product pipeline and the rising awareness of psoriasis and its treatment in developing countries which in turn is boosting the growth of the target market. Approval process of psoriasis drugs is becoming easier worldwide. For example, in Japan in 2019, the first regulatory approval of SKYRIZI (risankizumab) for the treatment of plaque psoriasis and the approval of a new treatment for plaque psoriasis in Europe in 2018. Hence, the increasing ease of drug approvals is anticipated to propel the psoriasis drugs market in the coming years.

 

 Download Free sample copy of this report @

https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/70

Key Highlights of Psoriasis Drugs Market:

  • In Aug 2021, SkinBioTherapeutics a UK based company has announced its first commercial product launch with a probiotic supplement developed to target psoriasis.
  • In Aug 2021, Dermavant Sciences announced the New Drug Application (NDA) of tapinarof for the treatment of plaque psoriasis in adults. The FDA has accepted and set the PDUFA target action date to Q2 2022.

 

Key Market Insights from the report:

 

Global Psoriasis Drugs Market accounted for US$ 15.85 billion in 2020 and is estimated to be US$ 37.07 billion by 2030 and is anticipated to register a CAGR of 8.90%. The global psoriasis drugs market is segmented based on therapeutic class, treatment, and region.

  • On the basis of Therapeutic Class, the Global Psoriasis Drugs Market is segmented into Tumor Necrosis Factor-inhibitors, Interleukin-inhibitors, Vitamin D analogues.
  • Based on Treatment, the target market is segmented into Topicals, Systemic, and Biologics.
  • By region, the Global Psoriasis Drugs Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is the worldwide leader in the psoriasis market in terms of revenue during forecast year due to the growing number of sufferers seeking treatment for the disease.

 

Competitive Landscape & their strategies of Psoriasis Market:

The key players operating the global psoriasis drugs market AbbVie, Inc., Pfizer Inc., Novartis, Eli Lilly and Company, Johnson & Johnson, Celgene Corporation, Amgen Inc., Boehringer Ingelheim GmbH, Merck & Co Inc., Janssen Biotech Inc, Bristol Myers Squibb, Arcutis Biotherapeutics, Skinbio Therapeutics, Dermurant Sciences, UCB, Renovatio Bioscience, EPI Health, LLC, MC2 Therapeutics, Almirall, Janssen Biotech Inc., Sun Pharma, Apremilast, Sandoz, Aditxt, Esker Therapeutics, Clover Biopharmaceutical, Mylan, Sienna Biopharmaceutical, Fresenius Kabi, Celltrion, Crescita Therapeutics, Glaxosmith Kline, Zydus Cadilla and many more. Prominent players operating in the target market are focusing on strategic partnerships as well as the launching of the Therapeutic Class to gain a competitive edge in the target market. For instance, on December 2017, Pfizer Inc. declared that the United States Food and Drug Administration (FDA) has approved XELJANZ 5 mg twice daily (BID) and XELJANZ XR (tofacitinib) extended-release 11 mg once daily (QD) for the treatment of adult patients with active psoriatic arthritis (PsA). It had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs (DMARDs).

Ask for [email protected]

https://www.prophecymarketinsights.com/market_insight/Insight/request-discount/70

The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report.

Some Important Points Answered in this Market Report Are Given Below:

  • Explains an overview of the product portfolio, including product development, planning, and positioning
  • Explains details about key operational strategies with a focus on R&D strategies, corporate structure, localization strategies, production capabilities, and financial performance of various companies.
  • Detailed analysis of the market revenue over the forecasted period.
  • Examining various outlooks of the market with the help of Porter’s five forces analysis, PEST & SWOT Analysis.
  • Study on the segments that are anticipated to dominate the market.
  • Study on the regional analysis that is expected to register the highest growth over the forecast period

 

Market Purview

  1. Market Dynamics, Regulations, and Trends Analysis
  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
    • Market Trends
    • DR Impact Analysis
    • PEST Analysis
    • Porter’s Five Forces Analysis
    • Opportunity Orbit
    • Market Investment Feasibility Index
    • Macroeconomic Factor Analysis
    •  Market Estimation
    • Top-Down Approach
      • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
      • Bottom-Up Approach
        • Approach for estimating market share by Bottom-up Analysis (Demand Side)
      • Market Breakdown and Data Triangulation
      • Research Assumptions

Global Psoriasis Drugs Market, By Therapeutic Class:

  • Tumor Necrosis Factor-inhibitors
  • Interleukin-inhibitors
  • Vitamin D Analogues

Global Psoriasis Drugs Market, By Treatment:

  • Topicals
  • Systemic
  • Biologics

Global Psoriasis Drugs Market, By Type:

  • Plaque Psoriasis
  • Psoriatic Arthritis
  • Others

Global Psoriasis Drugs Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Other Topics might be interested:

Global Skin Graft Blades Market, By Type (Allogeneic, Autologous, Xenogeneic, Prosthetic, and Isogeneic), By Graft Thickness (Split-Thickness, Full-Thickness, and Composite Graft), By Application (Burns, Extensive Wound, Skin Cancer, and Infection), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) – Trends, Analysis and Forecast till 2029

https://www.prophecymarketinsights.com/market_insight/Global-Skin-Graft-Blades-Market-4340

 

Global Diabetic Foot Ulcers Treatment Market, By Product Type (Wound Care Dressings (Foam Dressing, Hydrocolloid Dressing, Hydrogel Dressing, Alginate Dressing, and Other Dressing), Biologics (Growth factors, Skin Graft, and Skin Substitutes), Wound Care Therapy Devices (Negative Pressure Wound Devices, Hyperbaric Oxygen Therapy, and Other Wound Care Therapy Devices), and Others), By Ulcers Type (Neuropathic Ulcers and Neuro-Ischemic Ulcers), By Distribution Channel (Hospitals, Clinics, Ambulatory Surgical Center, and Homecare Setting), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) – Trends, Analysis and Forecast till 2030

https://www.prophecymarketinsights.com/market_insight/Global-Diabetic-Foot-Ulcers-Treatment-103

 

About Prophecy Market Insights

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

Media Contact
Company Name: Prophecy Market Insights
Contact Person: Sidhant
Email: Send Email
Phone: 8605312701
Address:964 E. Badillo Street #2042 Covina, CA 91724
City: Covina
State: California
Country: United States
Website: https://www.prophecymarketinsights.com/market_insight/Global-Psoriasis-Drugs-Market-By-70